{
  "first_published_at": "2012-10-30", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON199570", 
  "title": "Non-steroidal anti-inflammatory drugs (NSAIDs): further evidence that the cardiovascular risk with diclofenac is higher than other non-selective NSAIDs and similar to the selective COX-2 inhibitors", 
  "tags": "{\"parsed_therapeutic\": [\"pain-management-palliation\", \"rheumatology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Pain management and palliation\", \"Rheumatology\"]}", 
  "_document_number": 92, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "pain-management-palliation", 
    "rheumatology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Non-steroidal anti-inflammatory drugs (NSAIDs): further evidence that the cardiovascular risk with diclofenac is higher than other non-selective NSAIDs and similar to the selective COX-2 inhibitors</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: October 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--A new review on the cardiovascular safety of NSAIDs has highlighted further evidence that diclofenac is associated with cardiovascular risks that are higher than the other non-selective NSAIDs, and similar to the selective COX-2 inhibitors.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--&#160;&#160;<br />\nA new review on the cardiovascular safety of NSAIDs has highlighted further evidence that diclofenac is associated with cardiovascular risks that are higher than the other non-selective NSAIDs, and similar to the selective COX-2 inhibitors. Naproxen and low-dose ibuprofen are still considered to have the most favourable cardiovascular safety profiles of all non-selective NSAIDs.<br />\n<br />\nThis review, by the European Medicines Agency&#8217;s <a target=\"_blank\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000094.jsp&#38;mid=WC0b01ac0580028c79\">Committee on Medicinal Products for Human Use</a> (CHMP), evaluated all available data on this issue since the last review conducted in 2006.<br />\n<br />\nThe findings highlighted in this review are not new; an increase in risk of heart attack and stroke with some non-selective NSAIDs, such as diclofenac, particularly with long-term use of high doses and in patients who are already at high risk, is well recognised. Warnings have been included in the product information for healthcare professionals and patients, and in the BNF, for some years.<br />\n<br />\nThe need for any update to the existing treatment advice for diclofenac will now be assessed by the European Medicines Agency&#8217;s <a target=\"_blank\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000537.jsp&#38;mid=WC0b01ac058058cb18\">Pharmacovigilance and Risk Assessment Committee</a> (PRAC).<br />\n<br />\nHealthcare professionals are reminded that, when prescribing NSAIDs, patients should use the lowest effective dose for the shortest time necessary to control symptoms. The patient&#8217;s individual risk factors, including any history of cardiovascular and gastrointestinal illness, should also be taken into account.<br />\n<br />\n<strong>Further information:</strong><br />\n<a target=\"_blank\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/10/news_detail_001637.jsp&#38;mid=WC0b01ac058004d5c1\">Press release from the European Medicines Agency website</a><br />\nPrevious advice on NSAIDs from Drug Safety Update <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON088130 \">February 2009</a> and<a target=\"_blank\" href=\" http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084694 \"> December 2007</a><br />\n<a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/CardiovascularsafetyofCOX-2inhibitorsandnon-selectiveNSAIDs/index.htm]\">MHRA webpage on the cardiovascular safety of NSAIDs</a><br />\nBNF section 10.1 <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/PHP6435-voltarol-75-mg-sr.htm\">Drugs used in rheumatic diseases and gout </a><br />\n<br />\n<em>Article citation: Drug Safety Update October 2012, vol 6, issue 3: S1.</em>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t&#160;&#160;<br>\nA new review on the cardiovascular safety of NSAIDs has highlighted further evidence that diclofenac is associated with cardiovascular risks that are higher than the other non-selective NSAIDs, and similar to the selective COX-2 inhibitors. Naproxen and low-dose ibuprofen are still considered to have the most favourable cardiovascular safety profiles of all non-selective NSAIDs.<br>\n<br>\nThis review, by the European Medicines Agency&#8217;s <a target=\"_blank\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000094.jsp&amp;mid=WC0b01ac0580028c79\">Committee on Medicinal Products for Human Use</a> (CHMP), evaluated all available data on this issue since the last review conducted in 2006.<br>\n<br>\nThe findings highlighted in this review are not new; an increase in risk of heart attack and stroke with some non-selective NSAIDs, such as diclofenac, particularly with long-term use of high doses and in patients who are already at high risk, is well recognised. Warnings have been included in the product information for healthcare professionals and patients, and in the BNF, for some years.<br>\n<br>\nThe need for any update to the existing treatment advice for diclofenac will now be assessed by the European Medicines Agency&#8217;s <a target=\"_blank\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000537.jsp&amp;mid=WC0b01ac058058cb18\">Pharmacovigilance and Risk Assessment Committee</a> (PRAC).<br>\n<br>\nHealthcare professionals are reminded that, when prescribing NSAIDs, patients should use the lowest effective dose for the shortest time necessary to control symptoms. The patient&#8217;s individual risk factors, including any history of cardiovascular and gastrointestinal illness, should also be taken into account.<br>\n<br>\n<strong>Further information:</strong><br>\n<a target=\"_blank\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/10/news_detail_001637.jsp&amp;mid=WC0b01ac058004d5c1\">Press release from the European Medicines Agency website</a><br>\nPrevious advice on NSAIDs from Drug Safety Update <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON088130\">February 2009</a> and<a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084694\">December 2007</a><br>\n<a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/CardiovascularsafetyofCOX-2inhibitorsandnon-selectiveNSAIDs/index.htm%5D\">MHRA webpage on the cardiovascular safety of NSAIDs</a><br>\nBNF section 10.1 <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/PHP6435-voltarol-75-mg-sr.htm\">Drugs used in rheumatic diseases and gout</a><br>\n<br>\n<em>Article citation: Drug Safety Update October 2012, vol 6, issue 3: S1.</em>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-10-01", 
  "date_last_modified": "2013-02-06", 
  "_assets": [], 
  "_item_id": 92, 
  "summary": "", 
  "body": "Article date: October 2012     \nA new review on the cardiovascular safety of NSAIDs has highlighted further evidence that diclofenac is associated with cardiovascular risks that are higher than the other non-selective NSAIDs, and similar to the selective COX-2 inhibitors. Naproxen and low-dose ibuprofen are still considered to have the most favourable cardiovascular safety profiles of all non-selective NSAIDs.  \n  \nThis review, by the European Medicines Agency’s [Committee on Medicinal Products for Human Use](http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000094.jsp&mid=WC0b01ac0580028c79) (CHMP), evaluated all available data on this issue since the last review conducted in 2006.  \n  \nThe findings highlighted in this review are not new; an increase in risk of heart attack and stroke with some non-selective NSAIDs, such as diclofenac, particularly with long-term use of high doses and in patients who are already at high risk, is well recognised. Warnings have been included in the product information for healthcare professionals and patients, and in the BNF, for some years.  \n  \nThe need for any update to the existing treatment advice for diclofenac will now be assessed by the European Medicines Agency’s [Pharmacovigilance and Risk Assessment Committee](http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000537.jsp&mid=WC0b01ac058058cb18) (PRAC).  \n  \nHealthcare professionals are reminded that, when prescribing NSAIDs, patients should use the lowest effective dose for the shortest time necessary to control symptoms. The patient’s individual risk factors, including any history of cardiovascular and gastrointestinal illness, should also be taken into account.  \n  \nFurther information:  \n[Press release from the European Medicines Agency website](http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/10/news_detail_001637.jsp&mid=WC0b01ac058004d5c1)  \nPrevious advice on NSAIDs from Drug Safety Update [February 2009](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON088130) and[December 2007](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084694)  \n[MHRA webpage on the cardiovascular safety of NSAIDs](http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/CardiovascularsafetyofCOX-2inhibitorsandnon-selectiveNSAIDs/index.htm%5D)  \nBNF section 10.1 [Drugs used in rheumatic diseases and gout](http://www.medicinescomplete.com/mc/bnf/current/PHP6435-voltarol-75-mg-sr.htm)  \n  \nArticle citation: Drug Safety Update October 2012, vol 6, issue 3: S1.\n"
}